文献速递MDS 与骨髓增殖性肿瘤

SRSF2突变通过激活造血细胞中全局异常可变剪接程序驱动肿瘤发生

SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells.
PubMed 文献 · Leukemia · 2018-06-01

该研究利用HITS-CLIP技术确定SRSF2突变在体内如何全局影响RNA结合与剪接。多数差异结合事件并未转化为含SRSF2P95H结合位点外显子的可变剪接,剪接改变似以间接效应为主。SRSF2P95H靶标富集于RNA加工与剪接基因,提示「剪接级联」表型;HNRNPA2B1的剪接改变在体内损害造血分化。

要点

  • 多数差异结合事件未转化为含SRSF2P95H结合位点外显子的可变剪接,剪接改变以间接效应为主。
  • SRSF2P95H靶标富集于RNA加工与剪接基因,包括hnRNP和SR家族多个成员。
  • HNRNPA2B1的剪接改变在体内损害造血分化。

核心结论

  • 剪接因子中的复发性突变触发级联基因调控事件,共同影响造血并驱动癌症。

研究设计与样本

  • 利用HITS-CLIP在体内确定SRSF2突变如何全局影响RNA结合与剪接。

主要发现

  • 多数差异结合事件未转化为含SRSF2P95H结合位点外显子的可变剪接。
  • 剪接改变似以间接效应为主。
  • SRSF2P95H靶标富集于RNA加工与剪接基因,包括hnRNP和SR家族多个成员。
  • HNRNPA2B1的剪接改变在体内损害造血分化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recurrent mutations in the splicing factor SRSF2 are associated with poor clinical outcomes in myelodysplastic syndromes (MDS). Their high frequency suggests these mutations drive oncogenesis, yet the molecular explanation for this process is unclear. SRSF2 mutations could directly affect pre-mRNA splicing of a vital gene product; alternatively, a whole network of gene products could be affected. Here we determine how SRSF2 mutations globally affect RNA binding and splicing in vivo using HITS-CLIP. Remarkably, the majority of differential binding events do not translate into alternative splicing of exons with SRSF2P95H binding sites. Alternative splice alterations appear to be dominated by indirect effects. Importantly, SRSF2P95H targets are enriched in RNA processing and splicing genes, including several members of the hnRNP and SR families of proteins, suggesting a "splicing-cascade" phenotype wherein mutation of a single splicing factor leads to widespread modifications in multiple RNA processing and splicing proteins. We show that splice alteration of HNRNPA2B1, a splicing factor differentially bound and spliced by SRSF2P95H, impairs hematopoietic differentiation in vivo. Our data suggests a model whereby the recurrent mutations in splicing factors set off a cascade of gene regulatory events that together affect hematopoiesis and drive cancer.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Liang Y, Tebaldi T, Rejeski K, et al. SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells. Leukemia. 2018. PMID: 29858584. doi:10.1038/s41375-018-0152-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。